Peptides at a Turning Point: What’s Really Happening at the FDA?

Peptides have exploded into the health, longevity, and regenerative medicine conversation.

You hear about them on podcasts. You see them on social media. Patients are asking about them. Providers are using them. And increasingly, people are purchasing them online without fully understanding where they came from, what is actually in them, or whether anyone is monitoring their use.

At the same time, the regulatory landscape surrounding peptides has been changing.

So, what is actually happening?

On the Synergee Podcast, Lori Esarey and Kelly Cappasola sit down with Jim LaValle, RPh, CCN, Chair of the International Peptide Society, for an important conversation about peptides, the FDA, access, safety, and where this emerging area of medicine may be headed.

Jim brings a particularly valuable perspective to the conversation because he has been directly involved in the regulatory discussion, including providing testimony before the FDA.

And if you’ve been confused by the headlines surrounding peptides, this is an episode worth hearing.

Peptides Aren’t New—But the Conversation Around Them Is

Peptides are short chains of amino acids that function as signaling molecules in the body. While the recent attention may make peptide therapy seem like the newest health trend, peptides themselves are not a new concept. Our bodies naturally produce peptides, and peptide-based medications have been part of medicine for years.

What has changed is the enormous increase in public interest.

Peptides are now being discussed in connection with everything from:

● metabolic health and body composition

● muscle and physical performance

● recovery ● inflammation

● healthy aging and longevity

● tissue repair

● cognitive health

● overall resilience

But increased interest also brings increased responsibility.

Access Isn’t the Same Thing as Safety

One of the most important themes of this conversation is something we believe deserves much more attention: Just because you can buy something doesn’t mean you should.

A quick online search can lead consumers to countless peptide products, some labeled for “research use only,” with little assurance about what is actually in the vial. That raises very real questions. Where was it manufactured? Has it been independently tested? Is the stated concentration accurate? Is it sterile? Are there contaminants? Is this peptide even appropriate for the person using it? And perhaps most importantly: Who is overseeing the patient? There is an enormous difference between thoughtful peptide therapy used within a clinician-patient relationship and someone purchasing a substance online because they heard about it on social media.

So, What Is the FDA Doing?

This is where the conversation with Jim becomes especially interesting.

The FDA has been evaluating individual peptides and the circumstances under which certain substances may—or may not—be appropriate for pharmacy compounding.

That process has generated significant concern within the functional, regenerative, and compounding communities because regulatory decisions can ultimately affect whether clinicians and patients continue to have access to certain therapies.

Jim has been directly involved in advocating for a thoughtful, evidence-based approach to that process.

The goal isn’t simply to make every peptide available. And it shouldn’t be to eliminate innovation simply because a therapy doesn’t fit neatly within an existing model. The more productive question is: How do we create responsible access while maintaining appropriate standards for quality and patient safety?

2026 Could Be an Important Turning Point

Several peptides have recently received significant attention during the FDA advisory process, including compounds that clinicians in regenerative and functional medicine have been discussing for years. That movement has understandably generated excitement. But there is an important distinction that can easily get lost in headlines: An FDA advisory committee recommendation is not the same as FDA approval.

There are still regulatory steps involved. That nuance matters because the conversation shouldn’t become either:

“The FDA approved all these peptides!”

or:

“The FDA is trying to eliminate peptide therapy.”

The reality is considerably more complex. And that’s exactly why conversations with people who are actually participating in the process are so valuable.

We Need Both Innovation and Guardrails

At Synergee, we love exploring emerging therapies.

We also believe emerging medicine deserves thoughtful scrutiny. Those two positions can exist together. We can be excited about innovation while asking hard questions about safety. We can advocate for patient access while demanding quality. We can explore new therapeutic possibilities without pretending the science is further along than it actually is. And we can recognize that a promising therapy still needs to be used for the right person, for the right reason, with the right oversight. That’s what responsible personalized medicine should look like.

Peptides Shouldn’t Become the Next Quick Fix

There’s another side of the peptide conversation that is just as important. No advanced therapy replaces the foundations of health. You cannot peptide your way out of poor nutrition. You cannot replace resistance training with a peptide and expect to build a resilient body. You cannot ignore sleep, blood sugar, nutrient deficiencies, stress, movement, gut health, or metabolic dysfunction and expect one compound to solve everything. Peptides may eventually become an increasingly valuable part of personalized and regenerative medicine. But they are still one tool in a much larger toolbox. The foundation matters. It always will.

The Question Isn’t Just “Which Peptide Should I Take?”

As public awareness grows, this may be one of the most important mindset shifts we can make.

Instead of starting with: “What peptide should I take?”

Start with: “What am I trying to accomplish—and why isn’t my body doing that well already?”

That question changes everything. Maybe the issue is muscle loss. Maybe it’s insulin resistance. Maybe it’s poor recovery. Maybe it’s inadequate protein. Maybe it’s inflammation, sleep, hormones, nutrient status, or something else entirely. Once you understand the physiology, you can begin asking whether a particular therapy belongs in the strategy. That’s very different from choosing a peptide because someone online said it changed their life.

Where Does Peptide Medicine Go From Here?

We don’t know exactly what the peptide landscape will look like several years from now. That’s part of what makes this moment so interesting. Research is continuing. Regulations are evolving. Clinicians are advocating for clearer pathways. Patients are asking more sophisticated questions. And discussions that once took place primarily within specialized medical communities are now happening in the mainstream. What we hope emerges is not unrestricted access without accountability—and not regulation that unnecessarily eliminates potentially valuable therapies. We hope the future is one where science, safety, clinical judgment, quality, and responsible access can coexist. Because the bigger conversation isn’t simply about peptides. It’s about how medicine evolves. It’s about how we evaluate emerging therapies. And ultimately, it’s about how we bring innovation to patients responsibly.

Hear the Full Conversation

There is much more nuance to this discussion than we can capture in one article. Join Lori Esarey and Kelly Cappasola on the Synergee Podcast as they sit down with Jim LaValle, RPh, CCN, to unpack what is happening with peptides, what he’s seeing from inside the regulatory conversation, and what clinicians and consumers should understand moving forward.

WATCH THE FULL EPISODE ON YOUTUBE Peptides at a Turning Point: What the FDA Meeting Means for the Future Synergee: Where science, experience, and possibility come together. This content is provided for educational purposes only and is not medical advice. Peptides discussed may be investigational, may not be FDA-approved for specific uses, and their regulatory status and availability may change. Always discuss treatment decisions with an appropriately qualified healthcare professional.